scispace - formally typeset
D

David G. Ginzinger

Researcher at University of California, San Francisco

Publications -  60
Citations -  7747

David G. Ginzinger is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Cancer & Comparative genomic hybridization. The author has an hindex of 38, co-authored 59 publications receiving 7473 citations. Previous affiliations of David G. Ginzinger include University of British Columbia & Thermo Fisher Scientific.

Papers
More filters
Journal ArticleDOI

Cloning and mapping of the α-adducin gene close to D4S95 and assessment of its relationship to Huntington disease

TL;DR: The mapping of the adducin gene adjacent to D4S95 and its pattern of expression, as well as its potential for distinct alternately spliced variants, reinforces the necessity to accurately assess the role of the expression of this gene in the pathogenesis of HD.
Journal ArticleDOI

Ethnic and racial differences in prostate stromal estrogen receptor α

TL;DR: A relationship between a subset of genes and race/ethnicity using gene expression profiling was identified and Estrogen receptor α (ERα) was selected for confirmation due to its plausible biological role in cancer susceptibility.
Journal ArticleDOI

Real-time quantitative polymerase chain reaction: a potential tool for genetic analysis in neuropathology.

TL;DR: The uses of real‐time quantitative PCR are highlighted as a potential diagnostic tool in neuropathology, focusing on the analysis of CNS tumors.
Journal ArticleDOI

Diagnostic and Prognostic Value of Fas and Telomeric-Repeat Binding Factor-1 Genes in Adrenal Tumors

TL;DR: This investigation examined whether apoptosis-regulating genes, bcl-xL and fas, and a telomere-related gene, telomeric-repeat binding factor-1 (TRF-1), differ between adrenal cortical cancers and benign adrenal tumors.
Journal ArticleDOI

Efficient adenovirus-mediated ectopic gene expression of human lipoprotein lipase in human hepatic (HepG2) cells.

TL;DR: Strong in vitro evidence is provided that adenoviral-mediated ectopic expression of the human LPL gene could render hepatic cells capable of VLDL catabolism and thus support the possibility for in vivo adenOViral vector-mediated liver-targeted L PL gene therapy.